Benzinga | Jan 12, 2022 06:14AM EST

Needham Maintains Buy on Biogen, Lowers Price Target to $292

Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $328 to $292.